Competitor Analysis availables at pipeline stores

Newsletters

Weekly newsletter focused on antibodies, proteins & peptides, gene therapy, RNA and cell therapy, vaccines, biogenerics and related business. It contains brief abstracts of preclinical & clinical studies, regulatory updates and company news of the previous week, but for biologics only. Subscribe Now

Consultancy

Need consultancy on this topic? La Merie SL provides consultancy services to all clients who wish a fully personal, individual, strictly confidential and exclusive collaboration on a specific subject.

Coagulation Factors

 

Coagulation Factors

Competitor Analysis availables at Pipelinereview.com

Need consultancy on this topic?

The Competitive Intelligence Report Coagulation Factors as of February 2007 provides a competitor analysis in the development pipeline of novel coagulation factors such as fibrin, thrombin, factor VIIa (F. VIIa), factor VIII (F. VIII), factor IX (F. IX) and von Willebrand factor (vWF). The report also evaluates the market size and the product sales of marketed coagulation factors in 2006. Coagulation factors are used to prevent bleeding episodes in patients with hemophilia and currently evaluated in up side indications such as trauma bleeding. Novel engineered coagulation factors are also evaluated for treatment of bleeding in hemophilia patients with inhibitors against recombinant coagulation factors. Next generation improvements include protein formulations, devices, drug delivery technologies, engineered proteins or gene therapeutic approaches. The major players Novo Nordisk, Wyeth, Bayer Schering, CSL Behring, Novartis and Baxter are competing with each other by collaborations with innovator biotech companies.

 

Buy now a Competitor Analysis on:
Coagulation Factors